ABPI respond to statement of UK Government’s medicines regulation plans

In the response from the Association of the British Pharmaceutical Industry, Mike Thompson, ABPI Chief Executive said:
"This letter is a welcome recognition that the future of medicines regulation is a key priority for the Government as we negotiate a new relationship with the EU. It also signals a readiness to take a pragmatic approach to Brexit negotiations that puts people’s health first. This is a great first step and we look forward to seeing more detail in the coming weeks and months.

If patients in Europe are to continue to get safe and effective medicines in a timely fashion, the focus must be on agreeing regulatory partnership between the UK and the EU. The timeframes we need to meet to ensure no disruption or delay means that confirmation of a reciprocal approach from the EU would provide welcome certainty to more than 500 million patients.

ABPI aims to strengthen UK Life Sciences

The Association of the British Pharmaceutical Industry (ABPI) are at the heart of a health sector-wide effort, post-Referendum, that aims to establish consensus on key Brexit issues such as a regulation, trade, immigration and UK science. This has been to ensure that patients and public health are central to Brexit negotiations, and that UK Life Sciences is in as strong a position as possible as the UK establishes a new relationship with Europe.

This work is ongoing, and continues to involve more than 200 global experts from leading pharmaceutical and biotech companies; leading academic groups and research charities (such as the Wellcome Trust); the UK’s Medicines and Healthcare products Regulatory Agency (MHRA); the NHS and Public Health England; as well as a vast range of UK Government departments.